Indefinite Delivery Contract 75N93023D00016
Award Date
6/20/23
Last Date to Order
6/19/30
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Dynport Vaccine Company LLC
Ultimate Awardee
General Dynamics Corp
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) awarded a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract to Resourcepath, LLC, a certified Woman-Owned Small Business, to provide a comprehensive array of diagnostic pre-clinical services. The $12 million DIAGNOSTICS PRE-CLINICAL SERVICES PROGRAM IDIQ contract has a 7-year ordering period through June 2030. Under this contract,...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Contract to Dynport Vaccine Company LLC with a potential value of $30 million. The contract provides preclinical services for biopharmaceutical product development across five task areas from 2023 through 2030.
Task areas include product development planning and evaluation, analytical assay development and product characterization, process development and related...
This Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics. The contract, valued at a ceiling of $346,610,277, is for Early Phase Clinical Trial Units (EPCTU) services to support Phase 0 through Phase II clinical trials of investigational products targeting infectious diseases. The contract has a period of performance...
The federal contract IDV award, with an ID of 75N93024D00022, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS). This single-award Indefinite Delivery Contract, potentially valued up to $146,300,000, is for pre-clinical models of infectious diseases under task areas A, B, and C. The prime contractor, Texas Biomedical Research Institute, will provide a range of services including developing...
This is a single-award Indefinite Delivery Contract issued by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned for-profit organization that manufactures biologics. The Diagnostics Pre-Clinical Services Program IDIQ contract has a potential value of $24,000,000 over a 7-year ordering period ending June 2030.
Under this contract, ABL will provide a broad range of preclinical...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, awarded a $146.3 million Indefinite Delivery Contract (IDC) to Institute For Clinical Pharmacodynamics, Inc., a for-profit organization, to provide pre-clinical models of infectious diseases under Task Area C. The period of performance is from July 15, 2024 to July 14, 2031.
The contract is a follow-on to a previous Preclinical Models of Infectious Diseases...
This indefinite delivery contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. federal government, aims to provide the capability and capacity to develop and employ animal and animal replacement models of infectious diseases for screening, product evaluation, and eventual clinical evaluation. The single-award contract, with a 7-year ordering period and a ceiling value of $146.3 million, was awarded to Sigmovir Biosystems, Inc., a...
This federal contract award is an Indefinite Delivery, Indefinite Quantity (IDIQ) contract for the Diagnostics Pre-Clinical Services Program, awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases to the prime contractor MRI Global, also doing business as Midwest Research Institute. The contract has a potential value of $24,000,000 and a period of performance through June 2030. Under this IDIQ, MRI Global...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, awarded a multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The $107.3 million contract has a 7-year period of performance from...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030.
Services will be delivered under five task areas: product...